Ann Surg Treat Res.  2017 Dec;93(6):293-299. 10.4174/astr.2017.93.6.293.

Increased survival in hepatitis c patients who underwent living donor liver transplant: a case-control study with propensity score matching

• Kim JM
• Lee KW
• Song GW
• Jung BH
• Lee HW
• Yi NJ
• Kwon CH
• Hwang S
• Suh KS
• Joh JW
• Lee SK
• Lee SG

• KMID: 2396869
• DOI: http://doi.org/10.4174/astr.2017.93.6.293

Abstract

PURPOSE
There is no consensus regarding the difference in outcomes of HCV in patients who receive living donor liver transplantation (LDLT) or compared to deceased donor liver transplantation (DDLT). The aims of this study were to compare characteristics between LDLT and DDLT groups and to identify risk factors affecting patient survival.
METHODS
We retrospectively reviewed the multicenter records of 192 HCV RNA-positive patients who underwent liver transplantation.
RESULTS
Thirty-five patients underwent DDLT, and 146 underwent LDLT. The 1-, 3-, and 5-year patient survival rates were 66.7%, 63.0%, and 63.0% in the DDLT group and 86.1%, 82.3%, and 79.5% in the LDLT group (P = 0.024), respectively. After propensity matching, the patient survival curve of the LDLT group was higher than that of the DDLT group. However, there was no statistically significant difference in patient survival between the 2 groups (P = 0.061). Recipient age ≥ 60 years, LDLT, and use of tacrolimus were positively associated with patient survival in multivariate analyses.
CONCLUSION
LDLT appears to be suitable for HCV-infected patients if appropriate living donor is available.

Keyword

Hepatitis C virus; Immunosuppression; Living donors; Tacrolimus; Survival

MeSH Terms

Case-Control Studies*
Consensus
Hepacivirus
Hepatitis C*
Hepatitis*
Humans
Immunosuppression
Liver Transplantation
Liver*
Living Donors*
Multivariate Analysis
Propensity Score*
Retrospective Studies
Risk Factors
Survival Rate
Tacrolimus
Tissue Donors
Tacrolimus

Figure

• 

  Fig. 1 Survival curves of all LDLT and DDLT patients. LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation.

• 

  Fig. 2 Survival curves of propensity-matched LDLT and DDLT patients. LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation.

Reference

1. Shon HS, Choi HY, Kim JR, Ryu SY, Lee YJ, Lee MJ, et al. Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005-2012. Clin Mol Hepatol. 2015; 21:249–256.

2. Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, et al. Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study. Ann Surg Treat Res. 2016; 90:36–42.

3. Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014; 16:1–16.

4. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant. 2005; 5:549–557.

5. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013; 58:1028–1041.

6. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015; 15:17–38.

7. Olthoff KM, Smith AR, Abecassis M, Baker T, Emond JC, Berg CL, et al. Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg. 2015; 262:465–475.

8. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology. 2004; 40:699–707.

9. Hu A, Liang W, Zheng Z, Guo Z, He X. Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. J Hepatol. 2012; 57:1228–1243.

10. Mitchell O, Gurakar A. Management of hepatitis C post-liver transplantation: a comprehensive review. J Clin Transl Hepatol. 2015; 3:140–148.

11. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS Jr, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007; 13:122–129.

12. Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl. 2012; 18:1154–1170.

13. Terrault NA, Stravitz RT, Lok AS, Everson GT, Brown RS Jr, Kulik LM, et al. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology. 2014; 59:1311–1319.

14. Brown RS Jr. Living donor liver transplantation for HCV: will the true outcomes stand up? J Hepatol. 2012; 57:1166–1167.

15. Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation. 2011; 92:453–460.

16. Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol. 2012; 2012:686135.

17. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, et al. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology. 2011; 54:1313–1321.

18. Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol. 2014; 20:11095–11115.

19. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015; 148:108–117.

20. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016; 22:18–75.